This ruling removes a key IP barrier for competitors like Parse Biosciences, potentially accelerating market share erosion for 10x's core single-cell analysis products. Traders should monitor for any subsequent competitor product launches or licensing deals that exploit the invalidated patents, and watch for 10x's next quarterly report for any impact on revenue growth or market share commentary.
Price Chart
Executive Summary
The Federal Circuit affirmed PTAB decisions invalidating all claims of three 10x Genomics patents (’981, ’197, ’013) as obvious in IPRs brought by Parse Biosciences. This is a significant loss for 10x Genomics' patent portfolio covering core single-cell analysis methods, weakening its competitive moat and potentially exposing it to increased competition from Parse and other rivals. The ruling is final and nonprecedential but represents a material erosion of 10x's IP barriers in its key market.
Court Ruling Details
Key Facts
- Federal Circuit affirmed PTAB decisions that all claims of U.S. Patent Nos. 10,155,981, 10,240,197, and 10,697,013 are unpatentable as obvious.
- The three patents cover methods for analyzing nucleic acids from single cells, a core technology for 10x Genomics.
- The court rejected all four of 10x's challenges to the Board's motivation-to-combine and disclosure findings.
- The ruling is a final, nonprecedential disposition from the Federal Circuit, with no further appeal within the patent office.
- The IPRs were brought by competitor Parse Biosciences, which directly competes with 10x in single-cell analysis.
Financial Impact
Loss of patent protection on core single-cell analysis methods; no damages awarded as this is a patent invalidity ruling. The financial impact is the erosion of competitive barriers protecting 10x's revenue from single-cell products.
Risk Factors
- Increased competition from Parse Biosciences and other single-cell analysis companies now able to operate without infringement risk from these patents.
- Potential loss of licensing revenue if 10x had been licensing these patents to others.
- Possible negative sentiment on 10x's overall patent portfolio strength, potentially affecting partner/customer confidence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 court opinions from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-41ce2165bb-TXG |
| COURT-RULING Data (Synthetic) | court-3f0f4d9a7b-TXG |
| COURT-RULING Data (Synthetic) | court-ce52c07577-TXG |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | Insider Cluster | $70.11 $79.10 | ▲ +12.82% | ▲ +12.72% | $92.04 (+31.27%) |
Sep 3, 2026 28d ago | 144 | $63.22 $68.59 | ▼ −8.49% | ▼ −9.64% | $92.04 (−45.58%) |
Aug 28, 2026 4w ago | Insider Cluster | $62.45 $65.60 | ▲ +5.04% | ▲ +5.19% | $92.04 (+47.37%) |
Aug 26, 2026 5w ago | Insider Cluster | $64.85 $63.22 | ▼ −2.51% | ▼ −2.78% | $92.04 (+41.92%) |
Aug 20, 2026 6w ago | Institutional Cluster | $63.87 $64.85 | ▲ +1.53% | ▲ +0.42% | $92.04 (+44.10%) |
Aug 19, 2026 6w ago | Court Ruling | $62.19 $64.26 | ▼ −3.33% | ▼ −3.72% | $92.04 (−47.99%) |
Aug 17, 2026 6w ago | Insider Cluster | $57.99 $63.80 | ▲ +10.02% | ▲ +11.21% | $92.04 (+58.71%) |
Jul 5, 2026 12w ago | Institutional Cluster | $40.00 $42.73 | ▲ +6.83% | ▲ +6.34% | $92.04 (+130.09%) |
Jun 16, 2026 15w ago | 144 | $32.13 $34.60 | ▲ +7.69% | ▲ +8.73% | $92.04 (+186.45%) |
May 27, 2026 18w ago | Insider Cluster | $27.99 $33.50 | ▲ +19.69% | ▲ +19.37% | $92.04 (+228.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access